Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst David Nierengarten reaffirmed a Buy rating on Cogent Biosciences (COGT) with a $55 price target. This follows a recent Buy from LifeSci Capital, while Needham assigned a Hold rating to the stock today.
Wedbush analyst David Nierengarten maintained a Buy rating on Cogent Biosciences today and set a price target of $55.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Nierengarten is a 5-star analyst with an average return of 23.0% and a 54.93% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Damora Therapeutics, and Apogee Therapeutics.
In addition to Wedbush, Cogent Biosciences also received a Buy from LifeSci Capital’s Sam Slutsky in a report issued yesterday. However, today, Needham assigned a Hold rating to Cogent Biosciences (NASDAQ: COGT).